We are live on ! Find out more
SCM

Stonepine Capital Management Portfolio holdings

AUM $250M
1-Year Est. Return 77.6%
This Fund
S&P 500
This Quarter Est. Return
-40.93%
1 Year Est. Return
+77.6%
3 Year Est. Return
+198.76%
5 Year Est. Return
+226.15%
10 Year Est. Return
+1,976.54%
AUM
$94.6M
AUM Growth
-$48.9M
Cap. Flow
+$28M
Cap. Flow %
29.63%
Top 10 Hldgs %
59.92%
Holding
33
New
10
Increased
9
Reduced
7
Closed
7

Top Buys

1
LGND icon
Ligand Pharmaceuticals
LGND
+$14.6M
2
STML
Stemline Therapeutics, Inc.
STML
+$5.75M
3
GYRE icon
Gyre Therapeutics
GYRE
+$4.36M
4
BXRX
Baudax Bio, Inc. Common Stock
BXRX
+$4.12M
5
CDTX
Cidara Therapeutics
CDTX
+$3.9M

Top Sells

1
ADMS
Adamas Pharmaceuticals
ADMS
+$4.83M
2
AMRN
Amarin Corp
AMRN
+$3.96M
3
OXFD
Oxford Immunotec Global PLC Ordinary Shares
OXFD
+$3.58M
4
NVLN
Novelion Therapeutics Inc. Common Shares
NVLN
+$2.76M
5
APVO icon
Aptevo Therapeutics
APVO
+$2.73M

Sector Composition

1 Healthcare 91.21%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LGND icon
1
Ligand Pharmaceuticals
LGND
$6.08B
$11.7M 12.38%
+257,953
New +$14.6M
ISEE
2
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$8.89M 9.4%
2,583,786
-416,214
-14% -$2.43M
CTIC
3
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
$5.92M 6.26%
6,430,637
+2,675,637
+71% +$3.07M
AMRN
4
Amarin Corp
AMRN
$292M
$5.25M 5.55%
65,655
-11,910
-15% -$3.96M
AFMD
5
DELISTED
Affimed
AFMD
$4.74M 5.01%
300,000
-101,016
-25% -$2.41M
GYRE icon
6
Gyre Therapeutics
GYRE
$675M
$4.45M 4.71%
135,893
+94,921
+232% +$4.36M
STML
7
DELISTED
Stemline Therapeutics, Inc.
STML
$4.29M 4.54%
+886,632
New +$5.75M
XOMA
8
DELISTED
Xoma
XOMA
$4.25M 4.49%
208,600
+7,933
+4% +$183K
OPNT
9
DELISTED
Opiant Pharmaceuticals, Inc. Common Stock
OPNT
$3.65M 3.86%
380,948
+46,676
+14% +$559K
NEOS
10
DELISTED
Neos Therapeutics, Inc
NEOS
$3.52M 3.72%
4,690,146
-168,743
-3% -$232K
OXFD
11
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
$3.47M 3.67%
374,431
-256,431
-41% -$3.58M
EOLS icon
12
Evolus
EOLS
$377M
$3.42M 3.61%
822,960
+428,070
+108% +$3.63M
ADMS
13
DELISTED
Adamas Pharmaceuticals
ADMS
$3.36M 3.55%
1,162,876
-1,078,363
-48% -$4.83M
CPIX icon
14
Cumberland Pharmaceuticals
CPIX
$102M
$3.29M 3.48%
907,735
+11,565
+1% +$51.8K
APEN
15
DELISTED
Apollo Endosurgery, Inc.
APEN
$3.23M 3.42%
1,683,861
+32,528
+2% +$85.4K
CDTX
16
DELISTED
Cidara Therapeutics
CDTX
$3.23M 3.42%
+65,149
New +$3.9M
BDSI
17
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$2.86M 3.03%
+755,000
New +$3.71M
CHMA
18
DELISTED
Chiasma, Inc. Common Stock
CHMA
$2.72M 2.87%
744,134
+560,474
+305% +$2.49M
DMAC icon
19
DiaMedica Therapeutics
DMAC
$393M
$2.31M 2.44%
+825,297
New +$3.41M
SPNE
20
DELISTED
SeaSpine Holdings Corporation Common Stock
SPNE
$2.07M 2.19%
+253,131
New +$3.33M
AGTC
21
DELISTED
Applied Genetic Technologies Corporation
AGTC
$1.93M 2.04%
+586,969
New +$3.09M
BXRX
22
DELISTED
Baudax Bio, Inc. Common Stock
BXRX
$1.51M 1.6%
+436
New +$4.12M
IDXG
23
DELISTED
Interpace Biosciences, Inc. Common Stock
IDXG
$924K 0.98%
178,295
+83,910
+89% +$608K
ATRS
24
DELISTED
Antares Pharma, Inc.
ATRS
$357K 0.38%
+151,189
New +$514K
HTGM
25
DELISTED
HTG Molecular Diagnostics, Inc. Common Stock
HTGM
$323K 0.34%
5,515
-20,921
-79% -$2.05M
1
2

Similar funds

BIA
Bigelow Investment Advisors Portland, Maine $250M AUM 19.33% 1-Year Est. Return
TGP
TMT General Partner Hong Kong $250M AUM 6.05% 1-Year Est. Return
ER
EVR Research Richmond, Virginia $250M AUM 41.5% 1-Year Est. Return
FDDB
Fidelity D&D Bancorp Dunmore, Pennsylvania $249M AUM 18.9% 1-Year Est. Return
VM
VPR Management Houston, Texas $250M AUM 34.13% 1-Year Est. Return
PF
Parker Financial Silverdale, Washington $250M AUM 14.69% 1-Year Est. Return
SCM
Step Capital Management Singapore $249M AUM
CWM
Chicago Wealth Management Chicago, Illinois $251M AUM 45.31% 1-Year Est. Return

Stonepine Capital Management's Q1 2020 Portfolio in Review

As of Q1 2020, Stonepine Capital Management held 33 positions worth $94.6M, down 34% from $143M the previous quarter. Its ten largest holdings account for 60% of the portfolio.

Stonepine Capital Management deployed $28M of net new capital in Q1 2020, opening 10 new positions and adding to 9 existing holdings. Its largest new stake was Ligand Pharmaceuticals: 257,953 shares worth $11.7M.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, down from 92% a quarter earlier.

On the sell side, the largest reduction was Adamas Pharmaceuticals, an estimated $4.83M trimmed.

  • Stonepine Capital Management's largest Q1 2020 buy was Ligand Pharmaceuticals: 257,953 shares worth $11.7M.
  • Stonepine Capital Management added most to Gyre Therapeutics in Q1 2020, an estimated $4.36M increase.
  • Stonepine Capital Management's biggest Q1 2020 reduction was Adamas Pharmaceuticals, cutting an estimated $4.83M.
  • Stonepine Capital Management fully exited Novelion Therapeutics Inc. Common Shares in Q1 2020, selling an estimated $2.76M.
  • Stonepine Capital Management's ten largest holdings make up 60% of its $94.6M portfolio in Q1 2020.
  • Stonepine Capital Management opened 10 new positions and closed 7 in Q1 2020.
  • Stonepine Capital Management's portfolio value fell 34% quarter-over-quarter to $94.6M.

Based on Stonepine Capital Management's 13F filing for Q1 2020, filed 14 May 2020.